 lower morbidity and mortality
and a shorter hospitalization.80,81 Large studies designed
to evaluate the long-term (>5 years) outcomes have only
recently become available.82 Only one small series of
thoracic PAU showed a potential beneÔ¨Åt to TEVAR
because of a similar long-term survival (w50% at 10 years
in both groups), with lower morbidity in the TEVAR
group, despite being done in patients